Immunoglobulin, Antiserum, Antibody, Or Antibody Fragment, Except Conjugate Or Complex Of The Same With Nonimmunoglobulin Material Patents (Class 424/130.1)
  • Patent number: 10293049
    Abstract: The invention provides stabilized aqueous pharmaceutical etanercept compositions stabilized with an amino acid and suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: May 21, 2019
    Assignee: Coherus Biosciences, Inc.
    Inventors: Mark Manning, Brian Murphy
  • Patent number: 10294294
    Abstract: Synthetic fragment antigen-binding (Fab) antibodies are disclosed that bind to an N-terminal activation site of BCL-2-associated X-protein (BAX) and inhibit BAX activation. Also disclosed are methods of using the Fabs for measuring inactive monomeric BAX levels, screening for small molecules that bind to an N-terminal activation site of BAX, inhibiting apoptotic cell death, and predicting the ability of a cancer therapy to promote apoptotic cell death.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: May 21, 2019
    Assignees: Albert Einstein College of Medicine, The Governing Council of the University of Toronto
    Inventors: Evripidis Gavathiotis, Jonathan R. Lai, Sachdev Sidhu
  • Patent number: 10294285
    Abstract: Novel compositions of recombinant human CC10 protein have been generated by chemically modifying the pure protein in vitro. Several new synthetic preparations containing isoforms of chemically modified rhCC10 have been generated by processes that utilize reactive oxygen species and reactive nitrogen species. These preparations contain novel isoforms of rhCC10 which have been characterized with enhanced or altered biological properties compared to the unmodified protein. Preparations containing novel isoforms may be used as standards to identify and characterize naturally occurring isoforms of native CC10 protein from blood or urine and ultimately to measure new CC10-based biomarkers to assess patient disease status. These preparations may also be used to treat respiratory, autoimmune, inflammatory, and other medical conditions that are not effectively treated with the unmodified protein.
    Type: Grant
    Filed: July 17, 2016
    Date of Patent: May 21, 2019
    Inventors: Aprile L. Pilon-Clayton, Humcha K. Hariprakasha, Richard S. Clayton, Melissa E. Winn
  • Patent number: 10294480
    Abstract: A method for augmenting expression of a heterologous nucleic acid in a eukaryotic cell or increasing the efficiency of gene expression using any gene expression system is carried out by decreasing expression or activity of an endogenous Interferon-induced protein-16 (IFI16).
    Type: Grant
    Filed: May 5, 2014
    Date of Patent: May 21, 2019
    Assignee: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: David M. Knipe, Megan Horn Orzalli
  • Patent number: 10294305
    Abstract: Preparations and methods for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient, wherein the patient is not concomitantly treated with Interleukin-2 (IL-2), and wherein one or more treatment periods with the antibody may be preceded, accompanied, and/or followed by one or more treatment periods with a retinoid.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: May 21, 2019
    Assignee: APEIRON BIOLOGICS AG
    Inventors: Hans Loibner, Oliver Mutschlechner, Ruth Ladenstein, Isabel Klier
  • Patent number: 10287340
    Abstract: The invention provides single domain antibodies and derivatives thereof that bind antigens of interest, which are stable, soluble, and do not tend to aggregate. The invention also provides methods for constructing a dAb library and methods for screening dAb libraries to identify the dAb of the invention. The invention also provide methods of treating or preventing conditions by antigen neutralization by administering the dAbs of the invention.
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: May 14, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Dimiter S. Dimitrov, Weizao Chen
  • Patent number: 10286116
    Abstract: This document provides methods and materials involved in reducing venous neointimal hyperplasia (VNH) of an arteriovenous fistula (AVF) or graft. For example, methods and materials for using stem cells (e.g., mesenchymal stem cells), extracellular matrix material, or a combination of stem cells and extracellular matrix material to reduce VNH of AVFs or grafts are provided.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: May 14, 2019
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Sanjay Misra, Allan B. Dietz
  • Patent number: 10279037
    Abstract: This document provides methods and materials involved in modulating a cell's ability to be resistant to apoptosis. For example, methods and materials for exposing cells to KLK6 polypeptides, or increased KLK6 polypeptide activity, to promote resistance to apoptosis are provided. In addition, methods and materials for reducing the ability of KLK6 polypeptides to promote resistance to apoptosis are provided.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: May 7, 2019
    Assignee: Mayo Foundation for Medical Education and Research
    Inventor: Isobel A. Scarisbrick
  • Patent number: 10273301
    Abstract: The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of making and using same. Methods of use include methods of treatment of cancer, including leukemias, lymphomas, solid tumors and melanomas.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: April 30, 2019
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Linda Snyder, Gordon Powers
  • Patent number: 10273542
    Abstract: Biomarkers predictive of responsiveness to integrin beta7 antagonists, including anti-beta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of using such predictive biomarkers for the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn's disease.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: April 30, 2019
    Assignee: GENENTECH, INC.
    Inventors: Jason A. Hackney, Mary Keir, Gaik Wei Tew
  • Patent number: 10273312
    Abstract: We provide new monoclonal antibody inhibitors of coagulases for treatment of S. aureus. The monoclonal antibodies are useful in targeting the SC N-terminus and inhibiting SC-ProT activation. The monoclonal antibodies are able to bind to and interfere with, modulate, and/or inhibit the binding interactions between the staphylocoagulase protein and its ligand protein prothrombin in blood and tissues. The antibodies are effective in inhibiting the activation of prothrombin.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: April 30, 2019
    Inventor: William R Church
  • Patent number: 10266604
    Abstract: The present invention relates to CD27L antigen binding proteins, such an antibodies, polynucleotides encoding said CD27l antigen binding proteins, antibody drug conjugate compositions, and methods for diagnosing and treating diseases associated with CD27L expression.
    Type: Grant
    Filed: January 10, 2017
    Date of Patent: April 23, 2019
    Assignee: AMGEN INC.
    Inventors: John M. Delaney, William Christian Fanslow, III, Chadwick Terence King
  • Patent number: 10260067
    Abstract: Methods for enhancing wound healing, e.g., in diabetic subjects, by administering an antagonist of miR-26a, e.g., an inhibitory nucleic acid that targets miR-26a.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: April 16, 2019
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventor: Mark W. Feinberg
  • Patent number: 10258699
    Abstract: The present application relates to the molecular labeling and in vivo imaging of amyloids. Specifically, the present application relates to a polypeptide-based method/vector for targeting amyloids. Such a method/vector enables the transportation of compounds or drugs across blood-brain-barrier of an individual and then binding to amyloids in brain. Particularly, the vector of the present application can transport an imaging group linked to the vector across the blood-brain-barrier, and can binds to amyloids in brain, and thus enables the labeling and imaging of amyloid deposits. When used as an imaging agent for detecting amyloid deposits in body or tissues, the vector may be labeled with suitable optical imaging groups, radioactive isotopes or imaging groups suitable for MRI or CT detection.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: April 16, 2019
    Assignee: University Of Science and Technology of China
    Inventors: Jiangning Zhou, Chenwei Wang, Doudou Nan, Xinmeng Wang
  • Patent number: 10259877
    Abstract: The present invention relates to methods of migraine prophylaxis using anti-CGRP receptor antibodies or binding fragments. In particular, methods for preventing or reducing the occurrence of migraine headache in a patient in need thereof comprising administering to the patient an anti-CGRP receptor or binding fragment according to specific dosage regimens are disclosed. Pharmaceutical compositions and administration devices comprising anti-CGRP receptor antibodies or binding fragments for use in the methods are also described.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: April 16, 2019
    Assignee: AMGEN INC.
    Inventors: Hong Sun, Eduardo Dunayevich, Robert A. Lenz, Gabriel Vargas
  • Patent number: 10259864
    Abstract: Campylobacter jejuni is a leading cause of bacterial food-borne diseases in humans, ranging from acute diarrheal disease to neurological disorders. An isolated or purified antibody or fragment thereof specific to C. jejuni is described. The antibody or fragment thereof binds to a flagellar protein and reduces motility of C. jejuni. The antibody or fragment thereof is derived from a heavy chain IgG variable domain fragment (VHH) of a camelid animal immunized with C. jejuni flagellar protein. A multivalent form, as well as a phage format, of the antibody or fragment thereof is described. Methods of reducing presence of C. jejuni in an animal or an animal environment, methods and formulations for treating C. jejuni infection, and method of detecting C. jejuni are also described.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: April 16, 2019
    Assignee: National Research Council of Canada
    Inventors: Mehdi Arbabi Ghahroudi, Ali Riazi, Christine M. Szymanski, Greg Hussack, Jamshid Tanha, Roger MacKenzie
  • Patent number: 10258682
    Abstract: The invention provides vectors, attenuated pathogens, compositions, methods, and kits for use in preventing or treating infection by an infectious pathogen, especially Chlamydia trachomatis. The vectors comprise the plasmid encoded ppg genes from Chlamydia, ppg1, ppg2, ppg3, ppg5, ppg6, ppg7 and/or ppg8, but lack ppg4, a regulator of virulence associated genes. The application also provides attenuated pathogens, especially chlamydia, which are cured of their plasmid and have additional mutations to improve the attenuation, especially mutations in the CT135 gene or in the tryptophan operon (trp promoter, trpA, or trpB). Uses of said nucleic acids and attenuated pathogens for inducing or modulating an immune response in a subject, especially for prevention or treatment of infections, are proposed.
    Type: Grant
    Filed: January 16, 2014
    Date of Patent: April 16, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventor: Harlan D. Caldwell
  • Patent number: 10251930
    Abstract: The invention provides a method of treating a degenerative joint disease. The method comprises administering an effective amount of a pharmaceutical composition comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP). The invention also provides a pharmaceutical product as well as a kit comprising DA-DKP.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: April 9, 2019
    Assignee: Ampio Pharmaceuticals, Inc.
    Inventors: David Bar-Or, James V. Winkler
  • Patent number: 10233502
    Abstract: Biomarkers are provided for detecting, diagnosing and prognosing thymic cancer in individuals having or suspected of having thymic cancer. In addition, kits are provided for measuring expression levels or the presence of the biomarkers associated with thymic cancer for detecting, diagnosing and prognosing thymic cancer. Furthermore, methods are provided for detecting, diagnosing and prognosing thymic cancer in individuals having or suspected of having thymic cancer via the biomarkers.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: March 19, 2019
    Assignees: Indiana University Research and Technology Corporation, Castle Biosciences, Incorporated
    Inventors: Sunil Badve, Yesim Gokmen-Polar, Patrick J. Loehrer, Robert Cook, Derek Maetzold
  • Patent number: 10226514
    Abstract: A method of reducing blood glucose in a subject has been developed. In preferred embodiments, the method involves administering to the subject a specific activator of endogenous mitogen-activated protein kinase kinase 6 (MKK3), mitogen-activated protein kinase kinase 6 (MKK4), mitogen-activated protein kinase kinase 6 (MKK6), p38 mitogen-activated protein kinase (p38MAPK), mitogen-activated kinase-activated protein kinase 2 (MK2), or a combination thereof, in an effective amount to reduce blood glucose in a subject. In other embodiments, the method involves administering to the subject a specific activator to increase X-box binding protein 1 (XBP1) phosphorylation on Thr48 and Ser61 in an effective amount to reduce blood glucose in the subject. Methods of identifying agents for reducing blood glucose in a subject are also provided.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: March 12, 2019
    Assignee: The Children's Medical Center Corporation
    Inventors: Umut Ozcan, Jaemin Lee
  • Patent number: 10214590
    Abstract: Endoglin has been identified to play a functional role as a regulator of TGF?1 signaling, particular in TGF?1-mediated calcineurin expression. The present invention features methods of reducing cardiac damage, particularly in a subject undergoing chemotherapy or radiation therapy by administering a composition that inhibits endoglin activity. The present invention also features methods of treating autoimmune diseases, inflammatory diseases, organ transplantation, and conditions association with oxidative stress related to TGF?1-mediated calcineurin expression and reactive oxygen species (ROS) production by administering a composition that inhibits endoglin activity. The present invention also features methods of treating fibrotic diseases by administering a composition that inhibits endoglin activity.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: February 26, 2019
    Assignee: Tufts Medical Center, Inc.
    Inventors: Navin K. Kapur, Richard H. Karas
  • Patent number: 10214589
    Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: February 26, 2019
    Assignee: GENZYME CORPORATION
    Inventors: Clark Pan, Qun Zhou, James Stefano, Pradeep Dhal, Bo Chen, Diego Gianolio, Robert Miller, Huawei Qiu
  • Patent number: 10208128
    Abstract: The disclosure provides a HER3 binding polypeptide, comprising a HER3 binding motif, BM, which motif consists of the amino acid sequence selected from i) EX2X3X4A X6X7EIW X11LPNL X16X17X18QX20 X21AFIX25 X26LX28D, and ii) an amino acid sequence which has at least 90% identity to the sequence defined in i), wherein the polypeptide binds to the extra-cellular domain of HER3. Also provided is a bispecific ligand having binding affinity for HER3 and for HER2, or for HER3 and for EGFR, and comprising a HER3. binding polypeptide as defined herein and a HER2 binding polypeptide or a EGFR binding polypeptide.
    Type: Grant
    Filed: October 27, 2010
    Date of Patent: February 19, 2019
    Assignee: AFFIBODY AB
    Inventors: Fredrik Frejd, Elin Gunneriusson, Nina Kronqvist, John Löfblom, Stefan Ståhl
  • Patent number: 10206878
    Abstract: The present invention provides lyophilized formulations of active agents, particularly of TAT-NR2B9c including histidine, trehalose and lysine. TAT-NR2B9c has shown promise for treating stroke, aneurysm, subarachnoid hemorrhage and other neurological or neurotraumatic conditions. Such formulations are stable at ambient temperature thus facilitating maintenance of supplies of such a formulation in ambulances for administration at the scene of illness or accident or in transit to a hospital.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: February 19, 2019
    Assignee: NoNO Inc.
    Inventors: Jonathan David Garman, Frieder Hofmann
  • Patent number: 10206988
    Abstract: Compositions, methods of making, and methods of using, xenoantigen-displaying anti-cancer vaccines are described.
    Type: Grant
    Filed: November 28, 2016
    Date of Patent: February 19, 2019
    Assignee: The University Of Toledo
    Inventors: Steven J. Sucheck, Katherine A. Wall, Sourav Sarkar
  • Patent number: 10201610
    Abstract: A purified and isolated peptide comprises an amino acid sequence of SEQ ID NOs: 1 to 8. A method is also provided for preventing interaction, e.g. binding, of EN1 with EPRS in a cell by introducing, into the cell, a peptide having a sequence of SEQ ID NOs: 1 to 8, which results in the peptide interacting with EPRS thereby preventing an interaction of EPRS with EN1. Apoptosis can be induced in a cell expressing either or both of EN1 and EN2, by introducing into the cell, a peptide of SEQ ID NOs: 1 to 8.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: February 12, 2019
    Assignee: THE UNIVERSITY OF WESTERN AUSTRALIA
    Inventor: Pilar Blancafort
  • Patent number: 10202435
    Abstract: The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: February 12, 2019
    Assignee: ALDER BIOPHARMACEUTICALS, INC.
    Inventors: Maria-Cristina Loomis, Leon Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katherine Lee Hendrix, Ethan W. Ojala, Pei Fan, Jeffrey T. L. Smith, John A. Latham, Charlie Karasek, Jenny Mulligan, Michelle Scalley-Kim, Erica Stewart, Vanessa Lisbeth Rubin, Jens J. Billgren
  • Patent number: 10195281
    Abstract: The present application relates to formulations of anti-CD105 antibodies, antigen-binding fragments thereof, and uses thereof. Another aspect relates to pre-filled syringes of the formulations of anti-CD105 antibodies or antigen-binding fragments thereof. Another aspect relates to the use of the formulations to reduce one or more signs or symptoms of an angiogenesis-related disorder such as cancers and ophthalmologic diseases.
    Type: Grant
    Filed: September 5, 2013
    Date of Patent: February 5, 2019
    Assignee: Tracon Pharmaceuticals, Inc.
    Inventors: Suzanne Benedict, Mark Cornell Manning, Brian M. Murphy, Sharon Real, Charles Theuer
  • Patent number: 10195230
    Abstract: The present invention is a feed supplement consisting of a blood product from at least one Crocodylian species such as the American alligator (Alligator mississippiensis). The blood product is whole blood, hemolyzed blood, serum or plasma. The feed supplement is a liquid or solid. The feed supplement may be combined with a high nutrient feed or starter diet. The feed composition may contain 0.1% or more by weight of the feed supplement. The feed supplement is fed to weanling pigs or poultry hatchlings to increase their weight and feed intake. It is also expected to promote gut health.
    Type: Grant
    Filed: December 14, 2006
    Date of Patent: February 5, 2019
    Assignee: McNeese State University
    Inventors: Mark E. Merchant, Frederick LeMieux, Jr.
  • Patent number: 10191059
    Abstract: The present invention relates to the prognosis of the outcome of a cancer in a patient, which prognosis is based on the quantification of one or several biological markers that are indicative of the presence of, or alternatively the level of, the adaptive immune response of said patient against said cancer.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: January 29, 2019
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris Descartes
    Inventors: Jerome Galon, Franck Pages, Wolf-Herman Fridman
  • Patent number: 10191068
    Abstract: The invention relates to antibodies, antibody fragments and binding agents that specifically recognize TDP-43 associated with frontotemporal dementia (FTD), but not TDP-43 associated with amyotrophic lateral sclerosis (ALS) or TDP-43 associated with healthy human brain tissue, and antibodies, antibody fragments and binding agents that specifically recognize TDP-43 associated with ALS, but not TDP-43 associated FTD or TDP-43 associated with healthy human brain tissue.
    Type: Grant
    Filed: February 2, 2015
    Date of Patent: January 29, 2019
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Michael Sierks, Stephanie Williams, Lalitha Venkataraman
  • Patent number: 10179160
    Abstract: Described herein are materials and methods of treating dry eye disease in a subject.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: January 15, 2019
    Assignee: SCHEPENS EYE RESEARCH INSTITUTE
    Inventors: Reza Dana, Sunil Chauhan
  • Patent number: 10175244
    Abstract: The present invention relates to a mutated heat-shock protein 110 (HSP110) lacking its substrate binding domain, which does not exhibit its chaperon activity and/or is not capable of binding to best-shock protein 70 (HSP70) and/or to beat-shock protein 27 (HSP27), but which is capable of binding to a wild-type HSP110. Such a mutated heat-shock protein 110 can be used (i) in methods for proposing survival and/or the response to a treatment of a patient suffering from a cancer, more particularly from a cancer liable to have a microsatellite instability (MSI) phenotype, such as colorectal cancer (CRC), and (ii) for treating cancers.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: January 8, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITE DE BOURGOGNE
    Inventors: Carmen Garrido, Alex Duval
  • Patent number: 10172790
    Abstract: The present invention provides a method of suppressing the formation of a soluble association of an antibody in a solution; a method of suppressing the formation of a chemically degraded product of an antibody in a solution; and a method of stabilizing an antibody in a solution. The present invention also provides a solution-type antibody preparation in which the formation of a soluble association is suppressed; a solution-type antibody preparation in which the formation of a chemically degraded product is suppressed; a solution-type antibody preparation in which the formation of a soluble association, the formation of a chemically degraded product and the formation of an insoluble aggregate are suppressed; an agent for suppressing the formation of a soluble association of an antibody; an agent for suppressing the formation of a chemically degraded product of an antibody; and a stabilizing agent for an antibody.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: January 8, 2019
    Assignee: KYOWA HAKKO KIRIN CO., LTD
    Inventors: Yuji Ueno, Takashi Kayashita, Atsushi Ishihara, Masashi Nakakura, Kyoko Yamauchi
  • Patent number: 10174099
    Abstract: The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising an antigen-binding domain, wherein the antigen-binding domain of the first CAR binds to CD19 and the antigen-binding domain of the second CAR binds to CD22.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: January 8, 2019
    Assignees: UCL BUSINESS PLC, AUTOLUS LIMITED
    Inventors: Martin Pulé, Shaun Cordoba, Shimobi Onuoha, Simon Thomas
  • Patent number: 10174089
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: January 8, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Helen Hoerzer, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10174108
    Abstract: The present invention relates to antibody molecules, in particular antibody molecules that bind. Transforming Growth Factor beta (TGF?), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralize TGF?1, TGF?2 and TGF?3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: January 8, 2019
    Assignees: Genzyme Corporation, Optein, Inc.
    Inventors: Steven R. Ledbetter, Celia Patricia Hart, Robert G. Holgate, Lutz U. Jermutus, Catriona L. Buchanan, Alexander R. Duncan, Donna K. Finch
  • Patent number: 10167332
    Abstract: The invention provides a polypeptide containing at least one IgG Fc region region, said polypeptide having a higher anti-inflammatory activity and a lower cytotoxic activity as compared to an unpurified antibody and methods of production of such polypeptide.
    Type: Grant
    Filed: April 3, 2007
    Date of Patent: January 1, 2019
    Assignee: The Rockefeller University
    Inventors: Jeffrey V. Ravetch, Yoshikatsu Kaneko, Nimmerjahn Falk
  • Patent number: 10166293
    Abstract: The present application concerns concentrated protein formulations with reduced viscosity, which are particularly suitable for subcutaneous administration. The application further concerns a method for reducing the viscosity of concentrated protein formulations.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: January 1, 2019
    Assignees: Genentech, Inc., Novartis AG
    Inventors: Jun Liu, Steven J. Shire
  • Patent number: 10167337
    Abstract: Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-1, etc.) are demonstrated herein to be useful for the treatment of tumors.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: January 1, 2019
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: James Allison, Padmanee Sharma, Sergio A. Quezada, Tihui Fu
  • Patent number: 10167333
    Abstract: The invention is in the field of medical treatment and prevention. The invention provides an antibody or a part thereof capable of specifically binding to the Hepatitis B surface antigen (HBsAg) and having Hepatitis B Virus (HBV) neutralizing activity, wherein said antibody or fragment thereof comprises a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO: 5, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO: 6, a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO: 7, a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO: 8, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO: 9 and a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO: 10.
    Type: Grant
    Filed: January 15, 2015
    Date of Patent: January 1, 2019
    Inventor: Mario Umberto Francesco Mondelli
  • Patent number: 10155808
    Abstract: A monoclonal antibody against human PrPc protein capable of reducing the expression level of transcription factor Twist1 in a targeting mode and inducing macrophage and NK cells to target to rectal cancer tumor cells. The combined drug therapy with the antibody and cetuximab also exhibits inhibitory effect on tumor better than administration of the antibody or cetuximab alone.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: December 18, 2018
    Assignee: Institute of Zoology, Chinese Academy of Sciences
    Inventors: Quan Chen, Baowei Li, Haiying Hang, Lei Du, Jun Wang, Xiaohui Wang
  • Patent number: 10150813
    Abstract: The disclosure provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: December 11, 2018
    Assignee: Genentech, Inc.
    Inventors: Steven R. Leong, Andrew Polson, Paul Polakis, Yan Wu, Wei-Ching Liang, Ron Firestein
  • Patent number: 10150756
    Abstract: The present invention provides compounds of Formula (II) (e.g., compounds of Formula (I)), and pharmaceutically compositions thereof. Compounds of Formula (II) are believed to be binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (BET) proteins). Also provided are methods, uses, and kits using the compounds and pharmaceutical compositions for inhibiting the activity (e.g., increased activity) of bromodomains and/or bromodomain-containing proteins and for treating and/or preventing in a subject diseases associated with bromodomains or bromodomain-containing proteins (e.g., proliferative diseases, cardiovascular diseases, viral infections, fibrotic diseases, metabolic diseases, endocrine diseases, and radiation poisoning). The compounds, pharmaceutical compositions, and kits are also useful for male contraception.
    Type: Grant
    Filed: February 2, 2015
    Date of Patent: December 11, 2018
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: James E. Bradner, Jun Qi, Minoru Tanaka
  • Patent number: 10143750
    Abstract: The present invention relates to a method for the treatment of cancer in a subject which comprises the steps of: (i) administering electroporation to a tumour in the subject; and (ii) administering a T or B-cell activating agent to the subject, wherein step (i) and (ii) may be performed in either order.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: December 4, 2018
    Assignee: University College Cork
    Inventors: Declan Soden, Patrick Forde, Morgan O'Brien
  • Patent number: 10137170
    Abstract: Herein is reported a fusion polypeptide comprising i) one, two, three or four incretin receptor ligand polypeptides, and ii) one human immunoglobulin Fc-region, wherein at least one of the incretin receptor ligand polypeptides comprises an amino acid that is covalently conjugated to a lipid, and wherein each of the one, two, three or four incretin receptor ligand polypeptides is covalently conjugated by a peptide bond to a terminus of the human immunoglobulin Fc-region, whereby to each terminus of the human immunoglobulin Fc-region only a single incretin receptor ligand polypeptide is conjugated.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: November 27, 2018
    Assignees: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION, HOFFMANN-LA ROCHE INC.
    Inventors: Sara Belli, Konrad Bleicher, Richard D. Dimarchi, Eike Hoffmann, Eric A. Kitas, Anish A. Konkar
  • Patent number: 10131706
    Abstract: A pharmaceutical composition includes an isolated anti-Bb antibody or antigen binding portion thereof produced by a hybridoma cell line deposited under ATCC Accession Number PTA-8543 or an isolated anti-Bb antibody or antigen binding portion thereof that competitively inhibits binding of the antibody or antigen binding portion produced by the hybridoma cell line deposited under ATCC Accession Number PTA-8543 to the Bb segment of factor B; and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: November 20, 2018
    Assignee: NOVELMED THERAPEUTICS, INC.
    Inventor: Rekha Bansal
  • Patent number: 10131711
    Abstract: A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.
    Type: Grant
    Filed: May 4, 2015
    Date of Patent: November 20, 2018
    Assignee: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Kenya Shitara, Kazuyasu Nakamura, Emi Hosaka, Akiko Shimizu, Masamichi Koike
  • Patent number: 10125166
    Abstract: Provided herein is a novel epitope that can be used as a tag in methods for rapid and effective characterization, purification, and subcellular localization of polypeptides of interest, which comprise the tag. The tag is specifically recognized by an epitope specific antibody, which can be used to detect, capture, quantify, and/or purify polypeptides of interest that are tagged with the epitope. Also provided is novel epitope specific antibody.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: November 13, 2018
    Assignees: ChromoTek GmbH, NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen
    Inventors: Ulrich Rothbauer, Oliver Poetz, Tina Romer, Andrea Buchfellner, Larisa Yurlova, Kourosh Zolghadr, Jaqueline Bogner, Benjamin Ruf
  • Patent number: 10125187
    Abstract: This invention provides antibodies or fragments thereof that are capable of specifically binding to at least one conformational epitope of enterovirus 71 (EV71), wherein the antibody individually comprises at least one variable light chain and at least one variable heavy chain. There is also provided a method of producing an antibody capable of specifically binding to at least one conformational epitope of enterovirus 71 (EV71).
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: November 13, 2018
    Assignee: MAB Explorations Sdn Bhd
    Inventor: Mary Jane Cardosa